Enliven director sells 10,000 shares under plan
Enliven Therapeutics director Lori Anne Kunkel reported open-market sales of 10,000 shares of Enliven Therapeutics, Inc. common stock on June 5, 2026, executed in multiple trades under a Rule 10b5-1 trading plan adopted on March 6, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Enliven Therapeutics director Lori Anne Kunkel reported open-market sales of 10,000 shares of Enliven Therapeutics, Inc. common stock on June 5, 2026, executed in multiple trades under a Rule 10b5-1 trading plan adopted on March 6, 2026.
The shares were sold in three transactions at weighted average prices of $34.2794, $35.3573, and $35.8187 per share. After these sales, she held 51,884 shares of common stock directly.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares
Net Sell
4 txns
Insider
Kunkel Lori Anne
Role
Director
Sold
10,000 shs ($345K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,779 | $34.2794 | $267K |
| Sale | Common Stock | 1,867 | $35.3573 | $66K |
| Sale | Common Stock | 354 | $35.8187 | $13K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 51,884 shares (Direct);
Common Stock — 0 shares (Indirect, See footnote)
Footnotes (6)
- F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026
- F2. This transaction was executed in multiple trades at prices ranging from $33.7383 to $34.7358. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3. The number of shares held reflects the transfer of 31,172 shares of Common Stock from Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE to the Reporting Person .
- F4. This transaction was executed in multiple trades at prices ranging from $34.759 to $35.7574. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5. This transaction was executed in multiple trades at prices ranging from $35.7595 to $35.9456. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F6. The shares were held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE.
Key Figures
Shares sold: 10,000 shares
Weighted average sale price 1: $34.2794 per share
Weighted average sale price 2: $35.3573 per share
+4 more
7 metrics
Shares sold
10,000 shares
Aggregate common stock sold on June 5, 2026
Weighted average sale price 1
$34.2794 per share
One of three reported sale transactions
Weighted average sale price 2
$35.3573 per share
One of three reported sale transactions
Weighted average sale price 3
$35.8187 per share
One of three reported sale transactions
Shares held after transactions
51,884 shares
Direct common stock ownership following June 5, 2026 sales
Trading plan adoption date
March 6, 2026
Rule 10b5-1 plan covering the reported sales
Net buy/sell direction
Net-sell of 10,000 shares
Form 4 transaction summary for June 5, 2026
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, revocable trust, open-market sale
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
revocable trust financial
"The shares were held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE."
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Enliven Therapeutics (ELVN) disclose for Lori Anne Kunkel?
Enliven Therapeutics disclosed that director Lori Anne Kunkel sold 10,000 shares of common stock on June 5, 2026. The Form 4 shows these were open-market sales executed in multiple trades under a pre-established Rule 10b5-1 trading plan.
Was the Enliven Therapeutics (ELVN) insider sale made under a Rule 10b5-1 plan?
Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted by Lori Anne Kunkel on March 6, 2026. Such plans pre-schedule trades, which can make the timing less indicative of near-term company outlook.
What role does the revocable trust play in Enliven Therapeutics (ELVN) holdings?
The filing notes that shares were held by the Lori Kunkel Revocable Trust and that 31,172 shares were transferred from the trust to Lori Kunkel. This clarifies movement from indirect trust ownership to her direct ownership of Enliven Therapeutics shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates